ProSense® Breast Cryoablation
Low‑risk early‑stage breast cancer (≤1.5 cm, ER⁺/PR⁺/HER2⁻, Ki‑67 < 15 %)
FDA‑cleared (commercial)Active
Key Facts
Indication
Low‑risk early‑stage breast cancer (≤1.5 cm, ER⁺/PR⁺/HER2⁻, Ki‑67 < 15 %)
Phase
FDA‑cleared (commercial)
Status
Active
Company
About IceCure Medical
IceCure provides a liquid‑nitrogen cryoablation platform for minimally invasive tumor destruction across multiple oncology indications.
View full company profile